Ildong Pharmaceutical’s R&D subsidiary ‘YUNOVIA (CEO Suh Jin-sik and Choi Sung-ku)’ was officially launched on November 1 as the date of division. As the first CEOs of Yunovia, President Suh Jin-sik (former Ildong Pharmaceutical COO) and Choi Sung-ku (former Ildong Pharmaceutical Research and Development Head) will take office as their respective representatives and lead the company.

With its launch, Yunovia plans to pursue business strategies such as investment attraction, open innovation, and licensing out, as well as development of existing new drug projects and pipelines.Yunovia has a pipeline of 6 to 7 core new drugs in the fields of metabolic and degenerative diseases, liver diseases, gastrointestinal diseases, and ophthalmic diseases. In addition, it has about 25 pipelines, including platform technology and microbiome projects as well as new drug research projects in progress in areas such as cancer, cardiovascular disease, neurological and mental diseases, infectious diseases, and lung and respiratory diseases.

Among these, 'ID110521156', a new drug candidate for metabolic diseases in the GLP-1 receptor agonist series targeting type 2 diabetes and obesity, and 'ID119040338', an A1·A2A receptor antagonist being developed as a treatment for Parkinson's disease, a degenerative disease, are being used by many global companies. The company explained that it is receiving interest from companies.

In addition to conducting clinical development for promising pipelines, Yunovia plans to pursue early out-licensing and open innovation at the candidate material stage to generate profits as well as create growth engines by attracting investment and securing alliance partners. An official from Yunovia said, “Yunovia is differentiated in that it inherits the abundant R&D capabilities and assets cultivated by Ildong Pharmaceutical and starts from a prepared state,” adding, “We are establishing ourselves as a specialized R&D company with a sustainable virtuous cycle structure with a competitive and promising pipeline.” “We will continue to evaluate,” he said.

"Original press release was made only in Korean by Ildong Pharm and this translated version was provided by Yunovia later for viewers' convenience."